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ABSTRACT 26 
In Alzheimer’s disease (AD), cerebral arteries, in contrast to cerebral microvessels, 27 
show both cerebral amyloid angiopathy- (CAA) dependent and -independent vessel wall 28 
pathology. However, it remains unclear whether CAA-independent vessel wall pathology 29 
affects arterial function thereby chronically reducing cerebral perfusion, and if so which 30 
mechanisms mediate this effect. To this end, we assessed the ex vivo vascular function of the 31 
basilar artery and a similar-sized peripheral artery (femoral artery) in the Swedish-Arctic 32 
(SweArc) transgenic AD mouse model at different disease stages. Further, we used 33 
quantitative immunohistochemistry to analyze CAA, endothelial morphology, and molecular 34 
pathways pertinent to vascular relaxation. We found that endothelium-dependent, but not 35 
smooth muscle-dependent vasorelaxation was significantly impaired in basilar and femoral 36 
arteries of 15-month-old SweArc mice compared to that of age-matched wildtype (WT) and 37 
6-month-old SweArc mice. This impairment was accompanied by significantly reduced levels 38 
of cyclic GMP (cGMP), indicating a reduced nitric oxide (NO) bioavailability. However, no 39 
age- and genotype-related differences in oxidative stress as measured by lipid peroxidation 40 
were observed. Although parenchymal capillaries, arterioles, and arteries showed abundant 41 
CAA in the 15-month-old SweArc mice, no CAA or changes in endothelial morphology were 42 
detected histologically in the basilar and femoral artery. Thus, our results suggest that in this 43 
AD mouse model dysfunction of large intracranial, extracerebral arteries important for brain 44 
perfusion is mediated by reduced NO bioavailability rather than by CAA. This finding 45 
supports the growing body of evidence highlighting the therapeutic importance of targeting 46 
the cerebrovasculature in AD.        47 
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NEW & NOTEWORTHY 53 
We show that vasorelaxation of the basilar artery—a large intracranial, extracerebral artery 54 
important for cerebral perfusion—is impaired independent of cerebral amyloid angiopathy in 55 
a transgenic mouse model of Alzheimer's disease. Interestingly, this dysfunction is 56 
specifically endothelium-related and is mediated by impaired nitric oxide–cyclic GMP 57 
bioavailability.  58 
 59 
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INTRODUCTION 79 
Cerebrovascular pathology is inherent to Alzheimer’s disease (AD), with several lines 80 
of evidence indicating that it also strongly contributes to the onset of the disease (1, 2, 4). 81 
However, the molecular mechanisms underlying cerebrovascular pathogenesis at the different 82 
AD stages remain unknown. Vascular amyloid β (Aβ) deposition, known as cerebral amyloid 83 
angiopathy (CAA), severely affects cerebrovascular functionality and instigates a plethora of 84 
vascular abnormalities that play critical roles in the onset and progression of AD. These 85 
include vasculitis, vascular smooth muscle cell (VSMC) loss, and blood-brain barrier (BBB) 86 
leakage (10, 12, 17, 29, 30). However, pathologic remodeling of cerebral arteries is also 87 
observed prior to onset of AD in the absence of CAA, indicating that CAA certainly 88 
exacerbates cerebrovascular pathology but is not required to initiate it (18, 21). Thus, 89 
investigating CAA-independent changes in the functionality of cerebral vessels in AD is 90 
important for the early diagnosis of the disease.       91 
Soluble oligomeric Aβ species decrease the vasodynamic capacity of cerebral 92 
penetrating arterioles, independent of the presence of CAA (6). Whether VSMC and/or 93 
endothelial cell functionality in the upstream, major intracranial cerebral arteries may be 94 
impaired in the absence of CAA as well is, however, not clearly delineated. Therefore, herein, 95 
we recorded endothelium-dependent and -independent ex vivo vasodilatation and -constriction 96 
of the basilar artery in a transgenic mouse model of amyloidosis harboring the human 97 
Swedish and Arctic AD double mutation (SweArc mice) (20).  This mouse model is 98 
characterized by progressive age-dependent cerebrovascular pathology, soluble  oligomeric 99 
Aβ species generation (13, 14, 16, 17), and  cerebral hypoperfusion both before and after 100 
CAA onset (14, 17, 22).  Additionally, we performed quantitative histological assessments of 101 
endothelial morphology, lipid peroxidation as a marker of oxidative stress, CAA, and cyclic 102 
GMP (cGMP) as a readout of nitric oxide bioavailability. We used 6- and 15-month old 103 
SweArc and wildtype (WT) mice to discern age- from CAA-dependent mechanisms that 104 
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affect cerebral arterial function. So as to have a systemic artery control, we compared basilar 105 
artery relaxation to that of the similarly sized femoral artery. Using this experimental 106 
approach, we tested the hypothesis that dysfunction of large cerebral arteries in AD can also 107 
occur in the absence of CAA.          108 
 109 
 110 
MATERIALS AND METHODS 111 
Animals 112 
The basilar artery and distal portion of the femoral artery were isolated from 6- and 113 
15-month-old male SweArc mice (n = 8/age group) and their WT littermates (n = 7/age 114 
group) (C57Bl6/J background). Mice were housed under OHB conditions at the Laboratory 115 
Animal Services Center (LASC) of the University of Zurich (Zurich, Switzerland), with 116 
access to regular chow and water ad libitum. On the day of the experiments, mice were 117 
euthanized with carbon dioxide. All procedures and protocols were approved by the 118 
Veterinary Department (BVET; Swiss Animal Welfare Act, 2008, no. 455) of the Canton of 119 
Zurich and were performed according to the BVET guidelines. 120 
 121 
Organ chamber recordings 122 
Organ chamber recordings were performed non-blinded as previously described (26). Briefly, 123 
the femoral and basilar artery of the mice were dissected, excised, and placed in ice-cold 124 
modified Krebs–Ringer solution (in mmol/L: NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, 125 
NaHCO3 25.0, KH2PO4 1.18, calcium disodium EDTA 0.026, and glucose 11.1). Arterial 126 
rings were cut (0.8–1.4 mm in length, n ≥ 3/recording) and mounted in organ chambers 127 
containing Krebs-Ringer solution (37°C) aerated with 95% O2 and 5% of CO2, which were 128 
connected to a force transducer (M610 DMT, Inc., Denmark). The rings were stretched 129 
progressively to their optimal resting tension according to the manufacturer's protocol. 130 
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Internal circumference of the arteries was determined corresponding to a transmural pressure 131 
of 100 mmHg. The diameter of the artery was calculated according to its internal 132 
circumference. Changes in tension were expressed as a percentage of the reference 133 
contraction to U46619, a thromboxane A2 receptor agonist, obtained at the beginning of the 134 
experiment. Artery ring recordings were acquired in the presence of sodium nitroprusside 135 
(SNP) or acetylcholine (Ach) to study endothelium-independent and -dependent relaxation in 136 
a concentration–dependent manner. 137 
 138 
Histology 139 
Histological procedures were performed as previously described (17). Briefly, 140 
following induction of deep anesthesia, mice were transcardially perfused with phosphate-141 
buffered saline (PBS) and 4.0% paraformaldehyde (PFA) in PBS at room temperature, 142 
followed by incubation in 30% sucrose in PBS for 36 h. Cryoprotected brains were cut into 143 
35-μm thick free-floating sections, and were pretreated with proteinase K for antigen 144 
retrieval, immune-blocked, and incubated overnight at 4°C with an antibody against Aβ 145 
(purified mouse 6E10, 1:1000; Covance/Signet, SIG-39300), the endothelial marker CD31 146 
(rat anti-CD31/PECAM1, 1:50; BD Pharmingen, 553370), the VSMC marker alpha-smooth 147 
muscle actin (alpha-SMA) (goat anti-alpha-SMA, 1:250; Abcam, ab21027), cGMP (sheep 148 
anti-cGMP, 1:150; BioRad, OBT5055), and/or the lipid peroxidation marker 4-149 
hydroxynonenal (4-HNE) (rabbit anti-4-HNE, 1:200; Abcam, ab46545). The brain sections 150 
were subsequently incubated with secondary antibodies (a combination of either Alexa488-151 
conjugated donkey anti-rat IgG [1:750], Alexa594-conjugated donkey anti-goat IgG [1:750], 152 
and Alexa647-conjugated donkey anti-mouse IgG [1:500] or Alexa488-conjugated donkey 153 
anti-rat IgG [1:750], Alexa546-conjugated donkey anti-sheep [1:750], and Alexa405-154 
conjugated donkey anti-rabbit [1:750]; Jackson ImmunoResearch, Suffolk, UK) for 2 h at RT. 155 
Images were acquired in sequential mode and at a 1-µm step size interval using a confocal 156 
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microscope (Leica SP8; Leica, Wetzlar, Germany). They were processed as maximum 157 
projection z-stacks in Image J (National Institutes of Health, Bethesda, MA, USA) and were 158 
analyzed using an in-house generated MATLAB script based on the Imaging Toolbox of 159 
MATLAB (v2016b; MathWorks, Natick, MA, USA). 160 
 161 
Statistical analyses 162 
The data are presented as the mean ± SEM. For the artery ring experiments, two-way 163 
ANOVA followed by Bonferroni’s post-hoc comparison test was used; the histological data 164 
were analyzed using a two-tailed, nonparametric (Mann–Whitney)  Student’s t-test (GraphPad 165 
Prism, version 7; GraphPad Software, La Jolla, CA, USA). Differences were considered 166 
statistically significant at p < 0.05. 167 
 168 
 169 
  170 
 9
RESULTS 171 
General physiological parameters were assessed in the SweArc and WT mice to 172 
confirm comparable conditions in the two genotypes. As shown in Figure 1A, the diameter of 173 
the femoral and basilar artery was comparable in the SweArc and WT mice at both 6- and 15-174 
months of age, with an average luminal diameter of ~170 μm (6-month-old) and ~150 μm 175 
(15-month-old) for the femoral artery, and ~150 μm (6- and 15-month-old) for the basilar 176 
artery. Likewise, the resting tension of the femoral and basilar artery was similar between and 177 
among the 6- and 15-month-old SweArc and WT mice (~1.1 mN) (Fig. 1A). Body and heart 178 
weight in the 6-month-old mice was 29.8 ± 9.3 g and 0.13 ± 0.03 (SweArc), and 32.8 ± 7.1 g 179 
and 0.15 ± 0.03 g (WT), respectively; in the 15-month-old mice it was equal to 37.7 ± 11.2 g 180 
and 0.18 ± 0.04 g (SweArc), and 44.9 ± 7.9 g and 0.19 ± 0.03 g (WT), respectively.  181 
Next, we assessed endothelium- and VSMC-dependent vasorelaxation after U46619-182 
induced pre-contraction using acetylcholine and sodium nitroprusside (SNP), respectively 183 
(26). No significant differences in endothelium-dependent and –independent relaxation were 184 
observed between the two artery types of 6-month-old WT and SweArc mice (Fig. 1B). In 185 
contrast, femoral arteries of 15-month-old SweArc mice showed a significant decrease in 186 
endothelium-dependent relaxation compared to that of age-matched WT mice (AUC WT and 187 
SweArc: 851 ± 31.2 and 603 ± 30.5, respectively; p < 0.001) (Fig. 1C). This difference was 188 
exacerbated in the basilar artery of 15-month-old SweArc mice, showing a paradoxical 189 
vasoconstriction as opposed to the expected vasodilatation observed in the age-matched WT 190 
mice (AUC WT and SweArc: 778 ± 26.1 and 384 ± 69.7, respectively; p < 0.001). 191 
Endothelium-independent relaxation, on the other hand, was similar between the aged 192 
SweArc and WT mice (Fig. 1C).  193 
Given the specific impairment in Ach-induced, NO-mediated vasorelaxation with a 194 
paradoxical vasoconstriction observed in the 15-month-old SweArc mice, we assessed 195 
whether this might be related to reduced levels of cGMP, a marker of NO bioavailability. 196 
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Indeed, quantitative histological analysis of cGMP in free-floating brain sections containing 197 
the basilar artery showed a significant decrease in cGMP in the 15-month-old SweArc mice 198 
compared to that in age-matched WT littermate controls and in 6-month-old SweArc and WT 199 
mice (Fig. 2A–E). In line with the comparable Ach-induced vasorelaxation in the 6-month-old 200 
SweArc and WT mice, no significant differences in basilar artery cGMP levels were observed 201 
between these two groups. Further, no effect of aging on cGMP levels was observed in either 202 
the WT or SweArc mice (Fig. 2E).   203 
Aβ may increase reactive oxygen species (ROS) levels (24), thereby scavenging NO 204 
and diminishing its bioavailability (7). However, staining of the basilar artery for 4-HNE, a 205 
marker of lipid peroxidation and, thus, of oxidative stress, revealed equally low signals in 206 
both strains irrespective of age (Fig. 2A–E). This suggests that the observed reduced 207 
bioavailability of NO is not related to an increased scavenging by free radicals but perhaps to 208 
decreased NO production. Similarly, quantitative analysis of hyperplastic and/or hypertrophic 209 
changes in the endothelial cells of the SweArc basilar arteries that might underlie the 210 
observed decrease in cGMP showed no significant differences in these parameters between 211 
the SweArc and WT basilar arteries (Fig. 3A–C). These data confirmed that the differences 212 
observed were independent of morphological changes in the basilar artery endothelium.  213 
As we have previously shown, penetrating and intraparenchymal microvessels and 214 
arteries of SweArc mice show widespread CAA starting at around 8 months of age, which 215 
increases in severity with advancing age and has detrimental effects on the vasculature (14, 216 
17). In line with the above, staining for Aβ confirmed that the intraparenchymal vessels were 217 
affected by CAA in the 15-month-old SweArc mice (Fig. 4A); however, CAA was absent in 218 
the basilar artery (Fig. 4B) similar to the complete absence of parenchymal Aβ and CAA in 219 
the 15-month-old WT littermate controls (Fig. 4C and D). Of note, Aβ deposition in the 220 
vessel wall of peripheral arteries and microvessels is not observed in SweArc mice. 221 
 222 
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DISCUSSION 223 
We assessed systemic versus cerebral vascular function in a mouse model Alzheimer’s 224 
disease (AD) at different disease stages. We found CAA-independent endothelial dysfunction 225 
and reduced NO bioavailability, which was particularly accentuated in the basilar artery 226 
whereby paradoxical vasoconstrictions in response to Ach were observed. These findings may 227 
increase the understanding of the vascular pathology and related chronic cerebral 228 
hypoperfusion present at pre-AD stages where CAA is rare (9, 15, 23). Further, our findings 229 
are in line with our previous histological studies in human brain and those of others showing 230 
CAA-independent pathologic remodeling of vessel wall constituents regulating arterial 231 
vasodynamics (18, 21).  232 
Our finding of a histological reduction in cGMP content along with impairment in Ach-233 
induced vasorelaxation in the basilar artery of 15-month-old SweArc mice, is in line with that 234 
of another study (19). Although there the authors had not assessed vasodynamic responses as 235 
we did, they showed that both soluble and fibrillar Aβ impaired NO–cGMP signaling by 236 
inhibiting the activation of guanylate cyclase. Both these forms of Aβ are abundantly present 237 
in aged SweArc mice (14). Indeed, soluble protofibrillar Aβ species increase in an age-238 
dependent manner in SweArc mice, specifically from 8 months onward (16, 25), potentially 239 
explaining the unchanged basilar artery cGMP content and conserved responses to Ach in 6-240 
month-old SweArc mice.  241 
Given the absence of CAA in the basilar artery and the fact that the femoral artery also 242 
showed impaired endothelium-dependent relaxation, soluble Aβ species rather than CAA may 243 
be considered the key trigger of endothelial dysfunction in large cerebral arteries as observed 244 
in the 15-month-old SweArc mice. Soluble Aβ species are produced by VSMCs as well as 245 
neurons (8); the ones produced by the latter can also reach the vascular system through 246 
perivascular drainage routes (11, 12). Thus, the high level of soluble Aβ species observed in 247 
old SweArc mice combined with the vessel-directed Aβ clearance routes causes chronic 248 
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exposure of the vessel wall to high levels of toxic soluble Aβ species which, consequently, 249 
may alter NO levels (6).  Nevertheless, despite this high vessel wall exposure to soluble Aβ, 250 
the VSMC-dependent responses to SNP were comparable in wild type and SweArc mice, 251 
irrespective of age. This is in contrast to what we and others have previously shown for the 252 
deleterious effect of CAA on VSMC function and morphology (17, 18, 28).  253 
Our results indicate that, at least for the endothelium of the basilar and femoral artery, 254 
CAA is not a prerequisite for inducing endothelial dysfunction. However, although we did not 255 
detect CAA in the basilar artery, pathologic changes in the CAA-affected leptomeningeal and 256 
intraparenchymal vessels downstream of the basilar artery could still partially contribute to 257 
the observed vascular dysfunction as they are known to affect vascular integrity and function 258 
over large distances (5). Moreover, histological detection of vascular-related Aβ/CAA lacks 259 
the sensitivity that biochemical assays have for detecting (soluble) Aβ species in the vessel 260 
wall, thereby providing a limited assessment of the actual total vessel wall Aβ content (27). 261 
Aging per se impairs cerebrovascular function; therefore, cerebrovascular impairment 262 
due to aging and/or to AD pathology needs careful delineation. We previously showed age-263 
related impairment of endothelium-dependent basilar artery relaxation in WT mice (26). 264 
Thus, the similarly blunted vasorelaxation observed in the basilar artery of 6-month-old 265 
SweArc and 6- and 15-month-old WT mice in the present study is most likely an effect of 266 
aging. However, the exacerbated arterial dysfunction with a paradoxical vasoconstriction 267 
observed in 15-month-old SweArc mice indicates a combined effect of aging and Aβ-268 
mediated reduction in NO bioavailability.  269 
SweArc mice, like other transgenic AD mice, only partially model aspects of the vast 270 
cerebrovascular pathology that is present in AD (2), thus posing limits to the extrapolation of 271 
our results to the disease in humans. Nevertheless, taken together, our data add to the growing 272 
understanding of the multi-faceted vascular insults that contribute to AD (2, 3, 18). They 273 
especially shed much needed light on the functional implications of cerebrovascular 274 
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pathology in AD, and provide further evidence of the need for vascular-specific therapies to 275 
combat this disease.   276 
 277 
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FIGURE LEGENDS 401 
Fig. 1. General conditions and endothelium- and smooth muscle-mediated arterial relaxation 402 
of Swedish-Arctic and wildtype littermate control mice. A: Graphs representing the diameter 403 
and resting tension of the femoral and basilar artery of 15-month-old Swedish-Arctic 404 
(SweArc, n = 7) and wildtype (WT, n = 8) littermate controls. No significant changes in any 405 
of the parameters measured are observed between the two genotypes. B: Graphs showing the 406 
absence of significant differences in endothelium-dependent (acetylcholine- [Ach] induced) 407 
and vascular smooth muscle-dependent (sodium nitroprusside- (SNP) induced) relaxation 408 
between the basilar and femoral artery of 6-month-old SweArc (n = 7) and WT mice (n = 8) 409 
(artery rings: n ≥ 3/recording). C: Graphs showing a significant reduction in endothelium-410 
dependent relaxation of the femoral and basilar artery of 15-month-old SweArc mice as 411 
compared to that of their WT littermate controls. B and C: Smooth muscle-dependent 412 
relaxation is not affected in the 15-month-old SweArc mice. ***p < 0.001, referring to AUC.      413 
 414 
Fig. 2. Histological assessment of changes in the endothelial nitric oxide production marker 415 
cyclic GMP (cGMP) and of the presence of lipid peroxidation/oxidative stress in the basilar 416 
artery. A–D: Representative images of free-floating brain tissue sections at the level of the 417 
basilar artery of a 6- and 15-month-old wildtype (WT) littermate control and 6- and 15-418 
month-old Swedish-Arctic (SweArc) mouse stained for the endothelial cell marker CD31 419 
(green), cGMP (red), and the lipid peroxidation/oxidative stress marker 4-hydroxynonenal (4-420 
HNE). E: Quantification of the cGMP staining calculated as percentage of the CD31 staining 421 
shows a significant decrease in cGMP in the basilar artery of 15-month-old SweArc mice (n = 422 
5) compared to that in the basilar artery of 15-month-old WT littermates (n = 4), and of 6-423 
month-old WT (n = 3) and SweArc mice (n = 3). The percentage 4-HNE staining is equally 424 
low between the different groups. Scale bar in A and C = 50 μm. **p < 0.01, ***p < 0.001.  425 
 20
 426 
Fig. 3. Analysis of the number of endothelial cells and their morphology in the basilar artery. 427 
A: Representative images of free-floating brain tissue sections at the level of the basilar artery 428 
of a 15-month-old Swedish-Arctic (SweArc) and wildtype (WT) littermate control mouse 429 
stained for the endothelial cell marker CD31 (green). B: Quantification of the number of 430 
endothelial cells in five consecutive basilar artery sections of three SweArc and three WT 431 
mice reveals the absence of significant differences herein between the SweArc and WT 432 
littermate control mice. C: Similarly, no significant differences are observed in endothelial 433 
cell width between 15-month-old SweArc and WT littermate control mice. Scale bar in A = 50 434 
μm.  435 
 436 
Fig. 4. Distribution of cerebral amyloid angiopathy (CAA) in aged Swedish-Arctic mice and 437 
the absence of CAA and parenchymal amyloid β (Aβ) in wildtype (WT) littermate controls. 438 
A: Representative images showing the presence and wide-spread distribution of CAA-affected 439 
parenchymal arterioles (asterisk) and CAA-affected (penetrating) arteries (arrows) in the 440 
cortex of a 15-month-old SweArc mouse (CAA, red; CD31, green; alpha-smooth muscle actin 441 
[alpha-SMA], blue). Positive staining for alpha-SMA combined with vessel size confirms that 442 
the vessels indicated by arrows are arteries. B: Representative images showing the absence of 443 
CAA in the basilar artery of a 15-month-old SweArc mouse. C–D: Representative images 444 
showing the complete absence of CAA in both the intraparenchymal vessels and basilar artery 445 
of a 15-month-old WT littermate control mouse. Similarly, no parenchymal Aβ is detected in 446 
the WT littermate controls. The intensity of the alpha-SMA staining in B and D was increased 447 
using the “Brightness/Contrast” tool in ImageJ to allow proper visualization of the smooth 448 
muscle cell layers within the vessel wall.  Scale bar in A and C = 200 μm; in B and D = 50 449 
μm. 450 
 451 
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